astria therapeutics glp-1 receptor agonist weight management diabetes treatments GLP-1-based therapies for diabetes, obesity and beyond Frontiers | Exploring the multifaceted
Description
Standard appeals typically require a response within 30 days
However, pricing is shifting significantly
In people with T2D, the incretin effect is severely attenuated, despite similar levels of circulating GLP-1
doi: 10.3389/fendo.2019.00155 118 MaXLiuZIlyasILittlePJKamatoDSahebkaAet al
But a class of medications, initially approved to treat diabetes, is closing the gap between the two ends of the obesity treatment spectrum: lifestyle modification and bariatric surgery
currently, imports dominate
